Anti IL1RL1, ST2 Biosimilar – Anti-IL1RL1, ST2 mAb – Research Grade

Introduction

Anti IL1RL1, ST2 Biosimilar, also known as Anti-IL1RL1, ST2 mAb, is a research grade monoclonal antibody that specifically targets the IL1RL1/ST2 protein. This protein is a member of the interleukin-1 receptor family and is involved in various inflammatory and immune responses. The use of this biosimilar in scientific research has shown promising results in understanding the structure, activity, and potential applications of IL1RL1/ST2 as a therapeutic target.

Structure of Anti IL1RL1, ST2 Biosimilar

Anti IL1RL1, ST2 Biosimilar is a monoclonal antibody that is produced through recombinant DNA technology. It is a fully humanized antibody, meaning it is derived from human cells and has a high affinity and specificity for the IL1RL1/ST2 protein. The antibody consists of two heavy chains and two light chains, each with a specific amino acid sequence that determines its binding specificity. The binding region of the antibody is located on the variable region of the heavy and light chains, which recognizes and binds to the IL1RL1/ST2 protein.

Activity of Anti IL1RL1, ST2 Biosimilar

The primary activity of Anti IL1RL1, ST2 Biosimilar is to bind to the IL1RL1/ST2 protein and inhibit its function. IL1RL1/ST2 is a receptor protein that is activated by the cytokine interleukin-33 (IL-33), leading to the activation of various inflammatory pathways. By binding to IL1RL1/ST2, Anti IL1RL1, ST2 Biosimilar blocks the interaction between IL-33 and its receptor, thereby preventing the activation of inflammatory responses. This activity has been shown to be effective in reducing inflammation in various disease models, making Anti IL1RL1, ST2 Biosimilar a potential therapeutic option for inflammatory diseases.

Applications of Anti IL1RL1, ST2 Biosimilar

Anti IL1RL1, ST2 Biosimilar has been extensively used in scientific research to study the role of IL1RL1/ST2 in various diseases and to explore its potential as a therapeutic target. Some of the key applications of this biosimilar include:

1. Inflammatory Diseases IL1RL1/ST2 has been implicated in various inflammatory diseases, such as asthma, rheumatoid arthritis, and inflammatory bowel disease. By targeting this protein, Anti IL1RL1, ST2 Biosimilar has shown promising results in reducing inflammation and improving disease outcomes in preclinical studies. Further research is needed to explore its potential in clinical settings.

2.

Cancer

IL1RL1/ST2 has been found to be overexpressed in certain types of cancer, including breast cancer and lung cancer. This biosimilar has been used in research to investigate the role of IL1RL1/ST2 in cancer progression and to explore its potential as a therapeutic target in cancer treatment.

3. Biomarker for Disease Diagnosis IL1RL1/ST2 has been identified as a potential biomarker for various diseases, including heart failure, sepsis, and acute kidney injury. Anti IL1RL1, ST2 Biosimilar has been used in research to detect and measure the levels of this protein in different disease states, providing valuable insights into disease diagnosis and prognosis.

4. Drug Development The use of Anti IL1RL1, ST2 Biosimilar in research has also aided in the development of new drugs targeting IL1RL1/ST2. By understanding the structure and function of this protein, researchers have been able to design novel drugs that can specifically target IL1RL1/ST2 and potentially treat various diseases.

5.

Mechanism of Action Studies

Anti IL1RL1, ST2 Biosimilar has been a valuable tool in studying the mechanism of action of IL1RL1/